Bringing a dietary supplement to market in Poland does not begin with production or label design. It starts earlier, with checking whether the product has been classified correctly, whether the composition complies with regulations, and whether the documentation allows for a lawful market launch. In practice, this is exactly the stage at which many new brands make mistakes that later cause delays, label corrections, additional questions from authorities, or even the need to redesign the entire product concept.
The problem is that entrepreneurs often use a shortcut and say, “the supplement has to be registered with GIS.” That wording is convenient, but not entirely precise. In many cases, this is not about obtaining a classic approval before sale, but about submitting a notification of the first placement of a dietary supplement on the market. That difference has major practical and legal significance. If someone misunderstands this stage, they may have incorrect expectations about timing, documents, and the whole procedure.
Where the process of placing a supplement on the market really begins
Before the notification itself, several basic questions must be answered. The first is whether the product is definitely a dietary supplement, rather than a food for special purposes, a fortified food, a borderline product, or even a product that, because of its composition or manner of presentation, could be challenged as a medicinal product. This is not just a matter of naming. What matters is the composition, dosage, form of presentation, declared properties, and the language used on the label and in marketing materials.
The second question concerns composition. Even if the product concept appears commercially attractive, it still needs to be verified whether the ingredients are permitted for use in food or dietary supplements, whether their levels fall within safe and acceptable limits, and whether there are any ingredients that raise interpretive concerns. This is exactly the stage at which a sensible contract manufacturer or an experienced advisor can save a brand from many problems before the first finished batch is even made.
Notification to GIS is not the same as official product approval
This is the most important point to understand clearly. In everyday industry language, people often talk about “registering a supplement,” but in practice the procedure consists of notifying the Chief Sanitary Inspector about the first placement of the product on the market in Poland. This should not be confused with a classic administrative decision confirming that the product has been previously approved for sale in the same sense many people imagine, for example, in the case of medicines.
This distinction has real consequences. The notification initiates an information procedure and allows the authorities to assess the product, its composition, labeling, and presentation. However, it does not automatically mean that the entrepreneur receives formal “approval” in the form of a decision endorsing every formula before the launch. That is exactly why it is so important for the documentation to be prepared properly from the very beginning. If an entrepreneur relies only on the assumption that “the authority will check and approve everything,” they may seriously misjudge their own risk.
What information usually has to be prepared before filing a notification
A proper notification should not be built at the last minute. The basic data identifying the product, the entrepreneur, and the way the product will be presented must be gathered in advance. In practice, this includes such elements as the full product name, dosage form, qualitative and quantitative composition, recommended daily portion, details of the entity placing the product on the market, the labeling draft, and information allowing an assessment of how the product will function in the marketplace.
Consistency across all these elements is critical. If the formula, the label, the marketing claims, and the technical documentation are not speaking the same language, the risk of questions and doubts rises sharply. A typical mistake is that the marketing department prepares one version of communication, the technologist works with a different version of the formula, and the person responsible for documentation files the notification based on yet another data set. In that case, even a product built on a compliant composition can start to look formally uncertain.
The most common mistakes do not appear in the form itself, but around it
Many entrepreneurs assume that the most difficult part of the procedure is technically completing the notification form. In practice, the form is only the final step. Most problems arise earlier, in incorrect ingredient classification, imprecise raw material naming, inconsistencies between declared and technological quantities, or a poorly prepared label. Those are the elements that later return as the source of questions, corrections, and regulatory risk.
A very common mistake also concerns botanical ingredients. A brand enters a trade name or simplified name, but fails to provide the full and correct designation of the raw material, the plant part, the type of extract, or the standardization level. In the case of vitamins and minerals, there is often confusion between the amount of the compound and the amount of the active ingredient. These inaccuracies may look minor, but formally they matter a great deal.
The label is part of the legal risk, not just a sales tool
This is an issue that is often underestimated in practice. A brand wants packaging to be clear, modern, and commercially effective. That is of course important, but the label of a dietary supplement is not merely a marketing project. It is also an informational document assessed from the perspective of food law. Every statement concerning the product’s action, ingredients, or expected effect should be checked for legal permissibility.
This is precisely where some of the most common mistakes occur. Packaging may contain wording that is too medical, promises that resemble therapeutic action, overreaching simplifications, or unauthorized health-related associations. Even if the composition itself is compliant, the communication may create a regulatory problem. For the authority reviewing the product, it matters not only what is inside the capsule or sachet, but also how the product is presented to the consumer.
How long the whole process takes and where mismatched expectations come from
This is one of the most frequently asked questions. Entrepreneurs want to know how long they have to wait before the product can be sold and whether there is a fixed “registration” period. In practice, two different issues must be separated. One is the technical act of submitting the notification. The other is any further review and assessment of the product’s compliance with applicable law. That is why the answer regarding timing is not as simple as the market often expects.
The mismatch in expectations comes from the fact that companies confuse making the notification with achieving full formal certainty. Sending the notification itself is not the same as definitively closing all regulatory risks. In practice, the time needed for a safe market launch depends on the quality of the documentation, the type of ingredients used, the complexity of the formula, and whether the product contains straightforward elements or components likely to raise interpretive questions.
Most complications concern borderline products and “trendy” ingredients
Not every supplement is equally simple from a regulatory perspective. Products based on classic vitamins, minerals, and well-known ingredients are usually easier to organize than formulas containing novel raw materials, heavily promoted botanical extracts, nootropics, adaptogens, or ingredients whose legal status is debated. The more “modern” or aggressively positioned the product is, the greater the risk that it will be formally more difficult.
This is especially important for brands that want to enter the market quickly with a fashionable trend. In the supplement industry, time pressure is high, but that is also exactly when shortcuts are most dangerous. If a company wants to base its strategy on borderline ingredients or communication that comes close to prohibited health claims, it should be even more careful to organize documentation and compliance assessment before production begins.
Contract manufacturing can reduce risk, but it does not remove the brand’s responsibility
Working with an experienced contract manufacturer is very helpful, because it allows a brand to benefit from technological practice, support in composition development, and often also from know-how related to labeling and document preparation. That is a major advantage, especially for new brands. However, it does not mean that all responsibility shifts to the manufacturer. The entity placing the product on the market still has to understand what it is selling and on what legal basis it is doing so.
In practice, the best cooperation model is one in which the contract manufacturer and the brand work together at the product design stage. That makes it possible to identify problematic ingredients earlier, improve communication, refine the label draft, and reduce the risk that the finished product will become stuck at the formal stage or require expensive changes after the batch has already been produced.
Which documentation mistakes most often delay the process
- inconsistency between the formula, the label, and the notification data,
- imprecise designation of botanical ingredients, extracts, and standardization,
- incorrect calculation of active ingredient content per daily portion,
- use of wording suggesting medicinal or therapeutic action,
- lack of full control over source documents concerning raw materials,
- checking too late whether a given ingredient is actually suitable for safe use in a supplement formula.
Why the difference between notification and approval matters from a business perspective
This is not a subtle distinction only for lawyers. It is a difference that affects launch planning, production scheduling, marketing budgets, and the risk profile of the entire project. If a brand assumes that “once the notification is filed, everything is officially approved,” it may start sales activities too early, order too large a batch, or build communication that later has to be corrected. From a business standpoint, that is a very dangerous simplification.
A well-prepared brand should understand that notification is a mandatory and important element of lawful market entry, but it does not replace prior internal compliance control. The better this stage is prepared before production, the smaller the risk that formal requirements will delay sales or force costly corrections after packaging has already been printed and the product has already been manufactured.
Successful market entry for a supplement starts with order, not speed
In the supplement industry, it is easy to give in to the temptation to move fast. A market trend is growing, a brand wants to enter before competitors, so every stage is expected to happen “as quickly as possible.” The problem is that haste usually takes revenge precisely at the formal stage. An underdeveloped formula, an imprecise label, or an incorrect assumption about product status can set a project back much more than calmly preparing it correctly from the beginning.
That is why successful placement of a dietary supplement on the Polish market should be based on three pillars: correct product classification, reliable documentation, and a conscious approach to the GIS notification procedure. These are the elements that determine whether a brand will move through the process efficiently and without unnecessary losses, or whether it will only realize after the launch work has begun that regulatory formalities are not an add-on to the business, but one of its foundations.